CMC Icos Biologics, Inc., a clinical and commercial manufacturer of monoclonal antibodies, coagulation factors, and other therapeutic proteins, and Trellis Bioscience, a private, venture-funded therapeutic antibody company, have entered into a manufacturing agreement for the process development and production of two of Trellis’ monoclonal antibodies.

One antibody is for treating respiratory syncytial virus, and the second is for treating infections that are drug-resistant due to the formation of bacterial biofilms.

Source: CMC Icos Biologics